Effect of CD25 cell-surface marker expression on the integrated (combined cytogenetic and mutational) risk classification of AML. (A) Effect of CD25 on our previously published risk allocation that was determined by mutational profiling and redefined a substantial proportion of patients who by cytogenetic analysis (left) carried intermediate risk to favorable risk or unfavorable risk categories (middle).²⁶  When we incorporated CD25 expression into the integrated (combined cytogenetic and mutational status) risk stratification algorithm, an additional 11% of intermediate-risk patients were reallocated to the unfavorable-risk class. The favorable-risk group was unaffected by CD25 because of the rare occurrence of CD25 in favorable-risk patients. In each risk category, the percentage of patients in that cohort and their 3 years' OS are given. (B) Kaplan-Meier estimates of OS for the final risk groups, stratified by integrated risk (cytogenetic and mutational) and CD25 expression status.